Effect of Aloe vera capsule in control of gastroesophageal reflux disease

Phase 3

• Conditions: gastroesophageal reflux disease.; Diseases of oesophagus, stomach and duodenum; K20-K31

• Registration Number: IRCT20080901001165N42
• Lead Sponsor: Tabib daru pharmaceutical company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 December 2019

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Obtaining the informed consent of the patient.
Diagnosis of reflux has been confirmed by a physician Considering clinical and para clinical findings.
The patient's condition is not life-threatening.

Exclusion Criteria

Have been treated with any interactive medication before intervention; such as H2 blocker inhibitors and herbal medicines or drugs that are harmful to treatment for reflux such as theophylline and the like.
Participate in another clinical trial at the same time.
Pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bloat. Timepoint: Before intervention, 2 and 4 weeks after intervention. Method of measurement: Questionnaire.;Nausea and vomiting. Timepoint: Before intervention, 2 and 4 weeks after intervention. Method of measurement: Questionnaire.;Heartburn. Timepoint: Before intervention, 2 and 4 weeks after intervention. Method of measurement: Questionnaire.

Secondary Outcome Measures

Name	Time	Method
Quality of life. Timepoint: Before intervention, 2 and 4 weeks after intervention. Method of measurement: Heartburn/Reflux Symptoms Questionnaire.;Drug Adverse effects. Timepoint: After prescription of drug. Method of measurement: Data form.